Jefferies & Co Downgrades Accuray (ARAY) to Hold
More News related to ARAY
- Fox Chase Cancer Center Purchases CyberKnife System
- Vicenza Hospital Becomes First European Facility to Purchase Its Second CyberKnife System
- Accuray Incorporated to Present at 20th Annual Piper Jaffray Health Care Conference
- Accuray Receives Nasdaq Notification Related to the Late Filing of Form 10-Q
- Accuray Incorporated Ranked 55th Fastest Growing Company in North America on Deloitte's 2008 Technology Fast 500
More News related to Downgrades
- Post Properties (PPS) Announces Reduction In Quarterly Dividend To 20c, CIO Departure and New Stock Buyback Of Up To $200M
- Roberts Realty Investors (RPI) Increases Stock Repurchase Program
- United American Healthcare (UAHC) Approves $1 Million Stock Buyback
- Quidel Corporation (QDEL) Extends Current Stock Buyback Plan
- Quidel (QDEL) Adds $25M to Buyback Program
Jefferies & Co downgrades Accuray (Nasdaq: ARAY) from Buy to Hold. Price target $8.50.
Accuray Incorporated has developed the CyberKnife system, designed to treat solid tumors anywhere in the body as an alternative to traditional surgery.
Related Categories
DowngradesStocks Mentioned
+0.19Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
